H.C. Wainwright Thinks Bellerophon’s Stock is Going to Recover
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Bellerophon (BLPH), with a price target of $3. The company’s shares closed yesterday at $0.65, close to its 52-week low of $0.53.
“Our price target of $3/share is based on a discounted cash flow analysis (2019-2026) using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a development-stage drug company.”
According to TipRanks.com, Fein is a 3-star analyst with an average return of 1.1% and a 40.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and ACADIA Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bellerophon with a $2.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.33 and a one-year low of $0.53. Currently, Bellerophon has an average volume of 199.7K.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLPH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases.